Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors

Solid Tumor Cancer Clinical Trial

Official title:
A Phase I, Dose Escalation Study to Assess the Safety and Pharmacokinetics of SB- 485232 Administered as Daily Subcutaneous Injections in Adult Patients With Solid Tumors

Status Completed

Clinical Trial Summary

This is a phase I, open-label, dose-escalation study of SB-485232. Subjects will receive SB-485232 administered as subcutaneous injections daily for 14 days. Dose escalation (enrollment into the next cohort) cannot occur until all three subjects have completed the previous cohort; 5 doses will be tested. An additional dosing regimen has been added to evaluate higher doses given twice weekly for 7 weeks. Therefore, the full evaluation period for each patient will extend out to approximately eleven weeks after the first day of SB-485232 dosing.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Solid Tumor Cancer

Clinical Trial Details

NCT number	NCT00085878
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 1
Start date	January 2003

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00891761` - A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy	Phase 3
Completed	`NCT00046111` - A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00119171` - Ispinesib In Combination With Capecitabine In Patients With Solid Tumors	Phase 1
Recruiting	`NCT04354064` - Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Recruiting	`NCT02103920` - A Retrospective Immunohistochemistry Study of the Expression of Glycine/ Serine Pathway Molecules in Solid Tumors	N/A
Completed	`NCT00169520` - SB-715992 In Combination With Docetaxel In Patients With Solid Tumors	Phase 1
Completed	`NCT00136513` - SB-743921 In Patients With Solid Tumors	Phase 1
Completed	`NCT00085904` - Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas	Phase 1
Completed	`NCT06042400` - Trial of Written Exposure for Metastatic Cancer Patients (EASE)	N/A